Xometry (XMTR) is drawing fresh attention after rolling out new injection molding features that focus on accuracy, design feedback, and faster ordering. This raises questions about what this means for the stock’s long term story.

The product updates arrive after a sharp run in Xometry’s stock, with a 90 day share price return of 137.96% and a 1 year total shareholder return of 187.46%, suggesting momentum has been strong alongside other recent funding and partnership announcements.

If this kind of rapid platform development catches your eye, it might be worth widening your search to other AI focused manufacturing and software players through the 63 profitable AI stocks that aren't just burning cash.

So with Xometry now trading near US$93, above the current analyst price target of US$89.25 and still reporting annual net losses, is there still a buying opportunity here, or is the market already factoring in expectations for future growth?

Most Popular Narrative: 49.6% Overvalued

With Xometry trading at $93.28 against a most followed narrative fair value of $62.33, readers are effectively weighing a sizeable optimism premium in the current price.

Ongoing trends toward supply chain localization and resiliency are pushing more manufacturers, especially large enterprise customers, to seek flexible, domestic, and diversified sourcing solutions, increasing dependence on Xometry's platform and boosting high-value customer acquisition and revenue per customer.

Read the complete narrative. Read the complete narrative.

Want to see what kind of revenue ramp and margin uplift that story assumes? The fair value hinges on faster top line growth, rising profitability, and a rich future earnings multiple that would usually be reserved for premium growth stocks.

Result: Fair Value of $62.33 (OVERVALUED)

However, Xometry’s push into newer international markets and its ongoing net losses of $51.9 million could still challenge the optimistic growth and margin narrative.

Next Steps

With Xometry’s story pulling in both concerns and optimism, it makes sense to look at the full risk reward mix rather than rely on headlines alone. To see how the potential upsides stack up against the issues investors are watching, review the 1 key reward and 2 important warning signs.

Looking for more investment ideas beyond Xometry?

Do not stop your research with Xometry alone. Broaden your watchlist with other stocks that fit clear, rule based criteria using the Simply Wall Street Screener.

• Spot potential bargains early by reviewing companies on the 45 high quality undervalued stocks and see which stocks currently trade below their assessed worth.
• Prioritise resilience by checking out companies in the 66 resilient stocks with low risk scores and focus on stocks with more balanced risk profiles.
• Hunt for lesser followed opportunities by scanning the screener containing 20 high quality undiscovered gems and see which stocks combine quality fundamentals with limited attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.